INM — InMed Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1728328 ·
Last close
$1.51
Market Cap
$5.00M
52W High
$1.99
52W Low
$0.57
ADV30
3,383,472
Next earnings
2026-05-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,816,353 | -2,966,336 | 9,133,806 | 5,158,932 | 2,242,032 |
| Dec 2025 | 820,188 | 184,194 | -2,120,738 | -2,028,223 | 11,191,484 | 6,954,834 | 1,603,820 |
| Sep 2025 | 1,120,121 | 403,159 | -1,763,670 | -1,726,899 | 13,361,085 | 9,331,077 | 1,770,462 |
| Jun 2025 | 1,304,710 | 576,654 | -1,842,135 | -1,788,311 | 15,580,040 | 11,075,871 | 2,145,545 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,421,861
Investing CF
$0
Financing CF
$10,957,274
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.53
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-120,993,014
Inventory
$947,898
Receivables
$182,967
ST Investments
—
EBIT TTM
$-7,681,134
Pretax Income TTM
$-7,664,363
Interest Exp TTM
$371,549
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,942,633
EBITDA
$-7,834,568
Free Cash Flow
$-3,935,634
Enterprise Value
$223,825
Total Cash
$5,200,557
Total Debt
$420,147
Shares Out
3,314,063
Trailing EPS
$-1.47
Book Value
$2.08
ROE
-112.6%
ROA
-54.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 4,942,633 | -7,917,995 | -8,162,133 | 15,580,040 | 2,145,545 | — | -7,766,951 |
| Jun 2024 | 4,597,730 | -8,134,430 | -7,675,550 | 11,822,782 | 2,616,673 | — | -6,985,832 |
| Jun 2023 | 4,135,561 | -8,378,787 | -7,947,622 | 14,106,340 | 2,016,613 | — | -7,283,199 |
| Jun 2022 | 1,089,435 | -13,791,756 | -18,600,117 | 12,787,580 | 3,709,039 | — | -15,583,758 |
| Jun 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-6.25
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBIO | MUSTANG BIO, INC. | $4.97M | $0.74 | — |
| PPCB | Propanc Biopharma, Inc. | $4.90M | $2.15 | — |
| PULM | Pulmatrix, Inc. | $5.15M | $1.41 | — |
| DRMA | Dermata Therapeutics, Inc. | $4.83M | $1.20 | — |
| RNAZ | Transcode Therapeutics, Inc. | $5.20M | $5.47 | — |
News headlines (Yahoo Finance, 1h cache)
InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
2026-06-04 21:00 · Yahoo
/C O R R E C T I O N -- InMed Pharmaceuticals/
2026-05-20 14:34 · Yahoo
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)
2026-05-19 14:37 · Yahoo
A migraine drugmaker heads to the public markets through reverse merger
2026-05-19 11:19 · Yahoo
InMed Pharmaceuticals Amends Preferred Investment Options
2026-05-19 10:00 · Yahoo
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
2026-05-06 22:00 · Yahoo
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
2026-03-27 21:05 · Yahoo
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
2026-03-23 11:30 · Yahoo
Sidoti Events, LLC's March Small-Cap Virtual Conference
2026-03-18 12:00 · Yahoo
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
2026-03-09 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.